We enable safe and efficient monitoring of tissues during cancer surgery without compromising workflows.
Our vision is to be the leading manufacturer of aspirate tissue monitoring solutions by 2029.
Marginum is developing ground-breaking tissue recognition technology, especially for oncological surgery. Our technology enables safe and efficient identification of cancerous tissue with minimal damage to healthy tissues.
There is a globally growing need for efficient oncological treatments and accurate tissue identification is one of its biggest challenges during surgery. With our data-driven technology, we aim to radically improve surgical performance and patient outcomes. We prioritise patient welfare and adhere to the highest level of professionalism in everything we do. We respect the individual and by embracing diversity of thought, experience and background – we foster continuous learning and curiosity to deliver tangible value and lasting positive change. Our company can be only as successful as our team members and customers are.
Marginum’s pioneering work to radically improve surgical outcomes has already led to technological breakthroughs and received several academic and business awards. Our efforts will continue, and all is set for a rapid market entry in 2025.
FUTURE
2029Global leader in surgical tissue monitoring
2025Expansion to markets outside the EU
PAST
2025CE & Market Entry to EU
7/2024Commercialisation Project II
6/20241st Patent Granted
6/2024QMS Certification
5/20242nd Patent Application
11/2023Team Expansion
7/2023Seed Funding
5/2023 –Commercialisation Project I
4/20231st Major public project
4/2023MedLim Accelerator
12/2022Clinical Trials launched
11/2022 –Deep Tech Growth Program
11/2022Prototype assemblies completed
10/2022Product preorders received
7/2022Market validation
5/2022R&D Units Established
4/2022Winner Startup
3/2022Research Award
2/2022Research Grant
12/2021Pre-seed Funding
1/20211st Patent Application
11/2020Founded
1/2019Draft Program Winner
2016Basic Research
Marginum is a medical device company based in Kuopio, Finland.
Our team consists of multidisciplinary experts dedicated to improving surgical workflows with data-driven solutions.
Marginum is privileged to work together with clinical partners and global key opinion leaders in the field of neurosurgery and surgical technology.
Professor Fady T. Charbel is an internationally recognised key opinion leader in neurosurgery and mini-invasive surgical technology; awarded the prestigious AANS Cushing Award for Technical Excellence and Innovation in Neurosurgery. He is the Head of the Department of Neurosurgery at University of Illinois and has guided several medical innovations to the global markets (Transonic Systems Charbel Micro-Flow Probe®, VasSol NOVA® flow-analysis system).
Dr. Maria Severina has several decades of experience in high-quality development and product deployment across multiple industries and technologies, bringing businesses to successful commercialisation. Dr. Severina founded HyTest, the world’s leading antibody manufacturer and served as CEO for 26 years. She is a Board Member of several life science companies, including US-based Meridian Bioscience, and is actively involved with investments in life science start-up companies.
Kaj Hagros is Managing Partner at Redstone Nordics and has a broad history as an entrepreneur, investor and C-level executive with 25 years of experience. He is a board professional and has executed a wide array of early-stage investments and successful exits, and worked as CEO of Nasdaq Helsinki traded Tecnotree Corporation, COO of FOX Mobile and Head of Strategy & Business Development at Nokia Networks.
